BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 20836961)

  • 1. [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].
    Husted SE; Nielsen HK
    Ugeskr Laeger; 2010 Sep; 172(37):2522-6. PubMed ID: 20836961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].
    Husted SE; Nielsen HK
    Ugeskr Laeger; 2010 Oct; 172(42):2888-91. PubMed ID: 21040659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of antithrombotics for acute coronary syndromes in the emergency department: considerations and impact.
    Mukherjee D; Eagle KA
    Prog Cardiovasc Dis; 2007; 50(3):167-80. PubMed ID: 17976502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis.
    Kodumuri V; Adigopula S; Singh P; Swaminathan P; Arora R; Khosla S
    Am J Ther; 2011 May; 18(3):180-9. PubMed ID: 20027109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials.
    Eikelboom JW; Quinlan DJ; Mehta SR; Turpie AG; Menown IB; Yusuf S
    Circulation; 2005 Dec; 112(25):3855-67. PubMed ID: 16344381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial.
    Sabatine MS; Morrow DA; Montalescot G; Dellborg M; Leiva-Pons JL; Keltai M; Murphy SA; McCabe CH; Gibson CM; Cannon CP; Antman EM; Braunwald E;
    Circulation; 2005 Dec; 112(25):3846-54. PubMed ID: 16291601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of low-molecular-weight heparin in invasive management of non-ST-elevation acute coronary syndromes.
    Moser LR; Kalus JS
    Ann Pharmacother; 2004 Dec; 38(12):2094-104. PubMed ID: 15536140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of un-fractionated heparin and low molecular weight heparin on hospital mortality in patients with non ST elevation acute coronary syndrome (ACS).
    Angkasuwapala K; Ratanasumawong K; Ngarmukos T; Kehasukcharoen W; Boonsom W; Kamsa-ard S
    J Med Assoc Thai; 2007 Oct; 90 Suppl 1():109-14. PubMed ID: 18431893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.
    Eikelboom JW; Anand SS; Malmberg K; Weitz JI; Ginsberg JS; Yusuf S
    Lancet; 2000 Jun; 355(9219):1936-42. PubMed ID: 10859038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes.
    Magee KD; Sevcik W; Moher D; Rowe BH
    Cochrane Database Syst Rev; 2003; (1):CD002132. PubMed ID: 12535430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.
    Husted S; Kher A
    Ann Med; 2000 Dec; 32 Suppl 1():53-9. PubMed ID: 11209983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
    Collet JP; Montalescot G; Agnelli G; Van de Werf F; Gurfinkel EP; López-Sendón J; Laufenberg CV; Klutman M; Gowda N; Gulba D;
    Eur Heart J; 2005 Nov; 26(21):2285-93. PubMed ID: 15932908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin versus placebo for non-ST elevation acute coronary syndromes.
    Andrade-Castellanos CA; Colunga-Lozano LE; Delgado-Figueroa N; Magee K
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD003462. PubMed ID: 24972265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving role of low-molecular-weight heparins in ST-elevation myocardial infarction.
    Kalus JS; Moser LR
    Ann Pharmacother; 2005 Mar; 39(3):481-91. PubMed ID: 15701782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The medical management of acute coronary syndromes and potential roles for new antithrombotic agents.
    Pollack CV; Goldberg AD
    J Emerg Med; 2008 May; 34(4):417-28. PubMed ID: 18226874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes.
    Nicolau JC; Cohen M; Montalescot G
    J Cardiovasc Pharmacol; 2009 Jun; 53(6):440-5. PubMed ID: 19365279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of bleeding complications and 3-year survival with low-molecular-weight heparin versus unfractionated heparin for acute myocardial infarction: the FAST-MI registry.
    Puymirat É; Aissaoui N; Silvain J; Bonello L; Cuisset T; Motreff P; Bataille V; Durand E; Cottin Y; Simon T; Danchin N;
    Arch Cardiovasc Dis; 2012; 105(6-7):347-54. PubMed ID: 22800719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
    Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
    Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.